乳がんリキッドバイオプシー市場 - 成長、傾向、予測
Breast Cancer Liquid Biopsy Market - Growth, Trends, and Forecast (2020 - 2025)
|乳がんリキッドバイオプシー市場 - 成長、傾向、予測|
発行: Mordor Intelligence LLP
ページ情報: 英文 120 Pages
The Breast Cancer Liquid Biopsy Market is expected to register a CAGR of 18.9% during the forecast period. Breast cancer liquid biopsy is the method of detecting or investigating tumor cells in the blood sample obtained from the target cancerous site. For the detection of breast cancer, traditional methods like tissue biopsies are not comprehensive enough to predict or capture the entire genomics landscape of breast tumors. However, the presence of liquid biopsy as an alternative method allows for many clinical applications, including screening, detection of mutations, therapy selection, disease prognosis and drug response and resistance in patients who are unable to undergo an invasive tumor biopsy. According to World Health Organization (WHO), breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year, and it leads to highest number of cancer-related deaths among women. In the year 2018, it was estimated that approximately 627,000 women died from breast cancer that is nearly 15% of all cancer deaths among women globally. Rising prevalence of breast cancer and increasing demand for better minimally invasive therapies are the key driving factors in breast cancer liquid biopsy market.
Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share in the Breast Cancer Liquid Biopsy Market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global breast cancer liquid biopsy market due to the rising incidence of breast cancer cases and growing demand for non-invasive treatment in this region. According to the National Breast Cancer Foundation, in the year 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represents approximately 15.2% of all new cancer cases in the United States. Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and presence of well-established healthcare infrastructure is fueling the growth of the overall regional market to a large extent.
The Breast Cancer Liquid Biopsy Market is highly fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are QIAGEN, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Janssen Diagnostics, Biocept Inc, Guardant Health, Inc, Myriad Genetics, Adaptive Biotechnologies, Epic Sciences and Illumina, Inc.